Literature DB >> 15492823

Expression of Wnt genes and frizzled 1 and 2 receptors in normal breast epithelium and infiltrating breast carcinoma.

Tatjana Milovanovic1, Kestutis Planutis, Anthony Nguyen, J Lawrence Marsh, Fritz Lin, Christopher Hope, Randall F Holcombe.   

Abstract

The Wnt genes encode a family of related, secreted proteins which initiate a signal cascade upon binding to cell surface receptor molecules. The signaling pathway has been shown to be critical for normal growth and development in model organisms and is implicated in the genesis of numerous human cancers. Wnt proteins regulate mammary development in the mouse but their precise role in normal breast development and malignant transformation in humans remains poorly defined. In this study, we have examined the expression of several Wnt ligands by in situ anti-sense RNA hybridization in normal and malignant human breast tissue, as well as in several estrogen-responsive and estrogen-independent human breast cancer cell lines. The specific Wnt genes tested included Wnt1, Wnt2, Wnt4, Wnt5a, Wnt5b, Wnt6, Wnt7b and Wnt10b. We have also studied the expression of frizzled receptors 1 and 2 by immunohistochemistry in these tissues. Our results indicate that several of the Wnt ligands, especially Wnt1 and Wnt6, are strongly expressed in both normal and malignant breast tissue and that Wnt7b is down-regulated in breast cancer, compared to normal breast epithelium. The expression of frizzled 1 and 2 receptors was found to be up-regulated in breast cancer. These studies provide additional support to the hypothesis that the Wnt signaling pathway is involved in human breast cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15492823

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  46 in total

1.  Mesd is a universal inhibitor of Wnt coreceptors LRP5 and LRP6 and blocks Wnt/beta-catenin signaling in cancer cells.

Authors:  Wenyan Lu; Chia-Chen Liu; Jaideep V Thottassery; Guojun Bu; Yonghe Li
Journal:  Biochemistry       Date:  2010-06-08       Impact factor: 3.162

Review 2.  Development of anticancer agents targeting the Wnt/β-catenin signaling.

Authors:  Xiangqian Zhang; Jijun Hao
Journal:  Am J Cancer Res       Date:  2015-07-15       Impact factor: 6.166

Review 3.  Targeting Wnt pathways in disease.

Authors:  Zachary F Zimmerman; Randall T Moon; Andy J Chien
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-11-01       Impact factor: 10.005

Review 4.  Emerging targeted agents in metastatic breast cancer.

Authors:  Dimitrios Zardavas; José Baselga; Martine Piccart
Journal:  Nat Rev Clin Oncol       Date:  2013-03-05       Impact factor: 66.675

Review 5.  Gap Junctions and Wnt Signaling in the Mammary Gland: a Cross-Talk?

Authors:  Sabreen F Fostok; Mirvat El-Sibai; Marwan El-Sabban; Rabih S Talhouk
Journal:  J Mammary Gland Biol Neoplasia       Date:  2018-09-07       Impact factor: 2.673

Review 6.  Can we safely target the WNT pathway?

Authors:  Michael Kahn
Journal:  Nat Rev Drug Discov       Date:  2014-07       Impact factor: 84.694

7.  Increased WNT6 expression in tumor cells predicts unfavorable survival in esophageal squamous cell carcinoma patients.

Authors:  Lin Zhang; Gang Yuan; Yujing Fang; Miaozhen Qiu; Jianhua Lin; Jian Sun; Dajun Yang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

8.  Is there more to Wnt signalling in breast cancer than stabilisation of beta-catenin?

Authors:  Giovanna M Collu; Olivier Meurette; Keith Brennan
Journal:  Breast Cancer Res       Date:  2009-07-30       Impact factor: 6.466

9.  Modulation of the Wnt/beta-catenin pathway in human oligodendroglioma cells by Sox17 regulates proliferation and differentiation.

Authors:  Hui-Ling Chen; Li-Jin Chew; Roger J Packer; Vittorio Gallo
Journal:  Cancer Lett       Date:  2013-03-06       Impact factor: 8.679

10.  WNT signaling enhances breast cancer cell motility and blockade of the WNT pathway by sFRP1 suppresses MDA-MB-231 xenograft growth.

Authors:  Yutaka Matsuda; Thomas Schlange; Edward J Oakeley; Anne Boulay; Nancy E Hynes
Journal:  Breast Cancer Res       Date:  2009-05-27       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.